Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.

Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria.

Petrosillo N, Giannella M, Antonelli M, Antonini M, Barsic B, Belancic L, Inkaya A C, De Pascale G, Grilli E, Tumbarello M, Akova M.

Antimicrob Agents Chemother. 2014;58(2):851-8. doi: 10.1128/AAC.00871-13. Epub 2013 Nov 25.

2.

Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study.

Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME.

Respir Med. 2008 Mar;102(3):407-12. Epub 2007 Dec 3.

3.

Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.

Huang J, Tang YQ, Sun JY.

Scand J Infect Dis. 2010 Apr;42(4):260-5. doi: 10.3109/00365540903490018.

PMID:
20085424
4.

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.

Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A.

Int J Antimicrob Agents. 2010 Feb;35(2):194-9. doi: 10.1016/j.ijantimicag.2009.10.005. Epub 2009 Dec 16.

PMID:
20006471
5.

Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.

Zaidi ST, Al Omran S, Al Aithan AS, Al Sultan M.

J Clin Pharm Ther. 2014 Jun;39(3):272-6. doi: 10.1111/jcpt.12138. Epub 2014 Mar 5.

PMID:
24593154
6.

Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study.

Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G.

Clin Infect Dis. 2010 Dec 1;51(11):1238-44. doi: 10.1086/657242. Epub 2010 Oct 25.

PMID:
20973727
8.

Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series.

Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A.

Respir Med. 2009 May;103(5):707-13. doi: 10.1016/j.rmed.2008.11.018. Epub 2008 Dec 31.

9.

Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, Golmard JL, Rouby JJ; Nebulized Antibiotics Study Group.

Anesthesiology. 2012 Dec;117(6):1335-47. doi: 10.1097/ALN.0b013e31827515de.

PMID:
23132092
10.

Intravenous colistin administration in neonates.

Jajoo M, Kumar V, Jain M, Kumari S, Manchanda V.

Pediatr Infect Dis J. 2011 Mar;30(3):218-21. doi: 10.1097/INF.0b013e3182064bfe.

PMID:
21245777
11.

Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes.

Kwon KH, Oh JY, Yoon YS, Jeong YJ, Kim KS, Shin SJ, Chung JW, Huh HJ, Chae SL, Park SY.

Int J Antimicrob Agents. 2015 Jun;45(6):605-9. doi: 10.1016/j.ijantimicag.2015.01.011. Epub 2015 Feb 25.

PMID:
25772644
12.

Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.

Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H.

Int J Antimicrob Agents. 2014 Jan;43(1):52-9. doi: 10.1016/j.ijantimicag.2013.09.010. Epub 2013 Oct 16.

PMID:
24183799
13.

Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan.

Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM.

J Microbiol Immunol Infect. 2010 Aug;43(4):323-31. doi: 10.1016/S1684-1182(10)60050-3.

14.

Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.

Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP.

Int J Antimicrob Agents. 2014 Apr;43(4):349-52. doi: 10.1016/j.ijantimicag.2013.12.002. Epub 2013 Dec 15.

PMID:
24439066
15.

Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis.

Liu D, Zhang J, Liu HX, Zhu YG, Qu JM.

Int J Antimicrob Agents. 2015 Dec;46(6):603-9. doi: 10.1016/j.ijantimicag.2015.09.011. Epub 2015 Oct 19. Review.

PMID:
26607337
16.

Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.

Pintado V, San Miguel LG, Grill F, Mejía B, Cobo J, Fortún J, Martín-Dávila P, Moreno S.

J Infect. 2008 Mar;56(3):185-90. doi: 10.1016/j.jinf.2008.01.003. Epub 2008 Feb 15.

PMID:
18280570
17.

Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria.

Tumbarello M, De Pascale G, Trecarichi EM, De Martino S, Bello G, Maviglia R, Spanu T, Antonelli M.

Chest. 2013 Dec;144(6):1768-1775. doi: 10.1378/chest.13-1018.

PMID:
23989805
18.

Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.

Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME.

Antimicrob Agents Chemother. 2005 Aug;49(8):3136-46.

19.

Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria.

Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G.

Eur J Clin Microbiol Infect Dis. 2006 Sep;25(9):596-9.

PMID:
16955249
20.

Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction.

Turkoglu M, Dizbay M, Ciftçi A, Aksakal FN, Aygencel G.

Int J Antimicrob Agents. 2012 Feb;39(2):142-5. doi: 10.1016/j.ijantimicag.2011.10.006. Epub 2011 Nov 23.

PMID:
22115538

Supplemental Content

Support Center